Experienced in Spinocerebellar Degeneration and Corneal Dystrophy

Guillermo A. Izquierdo

Doctor Fedriani Avenue 3, 
Sevilla, AN, ES 
Experienced in Spinocerebellar Degeneration and Corneal Dystrophy
Doctor Fedriani Avenue 3, 
Sevilla, AN, ES 
OverviewLocationsClinical Research

Overview

Guillermo Izquierdo practices in Sevilla, Spain. Mr. Izquierdo is rated as an Experienced expert by MediFind in the treatment of Spinocerebellar Degeneration and Corneal Dystrophy. His top areas of expertise are Multiple Sclerosis (MS), Relapsing Multiple Sclerosis (RMS), CACH Syndrome, and Encephalitis.

His clinical research consists of co-authoring 200 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Spinocerebellar Degeneration and Corneal Dystrophy.

Gender
Male

Locations

Doctor Fedriani Avenue 3, Sevilla, AN 41009, Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
Enrollment Status: Completed
Publish Date: March 16, 2023
Intervention Type: Drug
Study Drug: Mavenclad®
Study Phase: Phase 4
Clinical Trial Phase I / II Multicenter, Randomized, Crossover, Double-blind Evaluation of the Safety and Feasibility of Systemic Therapy With Mesenchymal Cells Derived From Autologous Bone Marrow in Patients With Multiple Sclerosis
Clinical Trial Phase I / II Multicenter, Randomized, Crossover, Double-blind Evaluation of the Safety and Feasibility of Systemic Therapy With Mesenchymal Cells Derived From Autologous Bone Marrow in Patients With Multiple Sclerosis
Enrollment Status: Completed
Publish Date: April 06, 2022
Intervention Type: Other
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

199 Total Publications

First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: September 04, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Izquierdo's expertise for a condition
ConditionClose
    View All 8 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile